Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience

Shenmiao Yang, Ru Feng, Xutao Guo, Zhenling Li, Qianqian Ju, Yujun Dong, Bingjie Wang, Yu Zhao, Liang Wang, Wanling Sun, Fang Fang, Liru Wang, Liping Su, Xiaojun Huang

Blood (2024) 144 (Supplement 1): 7819.

https://doi.org/10.1182/blood-2024-210572

Published: 2024

Journal Articles

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Shenmiao Yang, Huayuan Zhu, Ru Feng, Xutao Guo, Ting Niu, Jian-Qing Mi, Zhenling Li, Qianqian Ju, Liru Wang, Yujun Dong, Bingjie Wang, Liang Wang, Wanling Sun, Fang Fang, Liping Su, Yu Zhao, Xiaojun Huang, Jianyong Li

Blood (2024) 144 (Supplement 1): 6773.

https://doi.org/10.1182/blood-2024-206560

Published: 2024

Journal Articles

Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML

Chenchen Zhao, MD, Bei Jia, MD PhD, Liru Wang, David F. Claxton, MD, W. Christopher Ehmann, MD, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Muhammad Khawaja, Raymond J. Hohl, Hong Zheng, MD PhD

Blood (2018) 132 (Supplement 1): 1526.

https://doi.org/10.1182/blood-2018-99-113547

Published: 2018

Journal Articles

Eomes + T-bet int CD8 T Cells Are Functionally Impaired and Associate with Primary Refractory Disease in Patients with Acute Myeloid Leukemia (AML)

Bei Jia, MD PhD, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Liru Wang, Todd D. Schell, Raymond J. Hohl, Hong Zheng, MDPhD

Blood (2017) 130 (Supplement 1): 108.

https://doi.org/10.1182/blood.V130.Suppl_1.108.108

Published: 2017

Journal Articles

Bone Marrow CD8 T Cells Express High Frequency of PD-1 and Exhibit Reduced Anti-Leukemia Response in AML Patients

Bei Jia, MD PhD, Liru Wang, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Hiroko Shike, Michael Bayerl, Todd D. Schell, Raymond J. Hohl, Hong Zheng, MDPhD

Blood (2017) 130 (Supplement 1): 3946.

https://doi.org/10.1182/blood.V130.Suppl_1.3946.3946

Published: 2017

Journal Articles

Very Low-Dose Decitabine Is Effective in Treating Intermediate or High Risk Myelodysplastic Syndrome

Blood (2016) 128 (22): 5536.

https://doi.org/10.1182/blood.V128.22.5536.5536

Published: 2016

NARROW

Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML

Eomes + T-bet int CD8 T Cells Are Functionally Impaired and Associate with Primary Refractory Disease in Patients with Acute Myeloid Leukemia (AML)

Bone Marrow CD8 T Cells Express High Frequency of PD-1 and Exhibit Reduced Anti-Leukemia Response in AML Patients

Very Low-Dose Decitabine Is Effective in Treating Intermediate or High Risk Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Outcomes and Clinical Practice Among Patient with Chronic Lymphocytic Leukemia Treated with Ibrutinib in China: A Real-World Experience

Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients

Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML

Eomes + T-bet int CD8 T Cells Are Functionally Impaired and Associate with Primary Refractory Disease in Patients with Acute Myeloid Leukemia (AML)

Bone Marrow CD8 T Cells Express High Frequency of PD-1 and Exhibit Reduced Anti-Leukemia Response in AML Patients

Very Low-Dose Decitabine Is Effective in Treating Intermediate or High Risk Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only